- Apremilast is associated with good effectiveness and acceptable safety in patients with psoriasis aged ≥65 years, according to a retrospective, real-world study.
Why this matters
- Real-world studies are needed for newly developed therapies, particularly in the elderly.
- 45.2% of patients achieved a Physician’s Global Assessment score of 0 or 1 between 3 and 6 months after initiation.
- 54.8% of patients stopped therapy:
- 56.6% stopped for adverse events.
- 23.7% stopped for primary failures.
- 9.2% stopped for relapses.
- Patients aged ≥75 years were more likely to discontinue because of adverse events (83.3%) compared with patients aged 65-74 years (45.3%; P=.007).
- Patients aged ≥85 years had a significantly lower continuation rate compared with younger patients (P=.01).
- 135 patients (mean age, 73.5 years) with psoriasis who received apremilast were included.
- Funding: None.